271980 — Jeil Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Jeil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	671,407	691,325	700,693	722,230	726,394
Cost of Revenue
Gross Profit	151,783	156,691	155,976	156,798	184,256
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	670,847	677,789	709,070	735,734	717,662
Operating Profit	560	13,536	-8,377	-13,504	8,731
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-554	12,552	-13,834	-13,247	1,916
Provision for Income Taxes
Net Income After Taxes	-10,239	6,965	-14,986	-15,009	5,201
Minority Interest
Net Income Before Extraordinary Items
Net Income	-10,239	6,916	-12,473	-13,091	5,005
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,239	6,916	-12,473	-13,091	5,005
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-712	449	-951	-899	343
Dividends per Share